About 26S proteasome non-ATPase regulatory subunit 6
26S proteasome non-ATPase regulatory subunit 6 (PSMD6) is a protein
from Homo sapiens identified by UniProt accession
Q15008, 389 residues long.
MolForge cross-references it against 0 known binders and
70 disease associations.
Target properties
| Protein name | 26S proteasome non-ATPase regulatory subunit 6 |
| UniProt accession | Q15008 |
| Gene | PSMD6 |
| Organism | Homo sapiens |
| Length | 389 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (70)
Diseases linked to this target (Open Targets).
- HIV infection · score 0.46
- type 2 diabetes mellitus · score 0.32
- breast adenocarcinoma · score 0.30
- endometrial cancer · score 0.29
- lung adenocarcinoma · score 0.28
- clear cell renal carcinoma · score 0.27
- gastric adenocarcinoma · score 0.27
- neurodegenerative disease · score 0.26
- mean corpuscular volume · score 0.19
- mean corpuscular hemoglobin concentration · score 0.17
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q15008-F1 | alphafold | PREDICTED | 82.39 | — |
Amino-acid sequence (389 residues)
MPLENLEEEG LPKNPDLRIA QLRFLLSLPE HRGDAAVRDE LMAAVRDNNM APYYEALCKS LDWQIDVDLL NKMKKANEDE LKRLDEELED AEKNLGESEI RDAMMAKAEY LCRIGDKEGA LTAFRKTYDK TVALGHRLDI VFYLLRIGLF YMDNDLITRN TEKAKSLIEE GGDWDRRNRL KVYQGLYCVA IRDFKQAAEL FLDTVSTFTS YELMDYKTFV TYTVYVSMIA LERPDLREKV IKGAEILEVL HSLPAVRQYL FSLYECRYSV FFQSLAVVEQ EMKKDWLFAP HYRYYVREMR IHAYSQLLES YRSLTLGYMA EAFGVGVEFI DQELSRFIAA GRLHCKIDKV NEIVETNRPD SKNWQYQETI KKGDLLLNRV QKLSRVINM
Explore 26S proteasome non-ATPase regulatory subunit 6 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets